Skip to main content

Table 6 Relationship between double positivity of anti-nuclesome and anti-C1q antibodies and other disease parameters among patients under study

From: Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Variable
n (%) or mean±SD
Double Positive
(n=22)
Double Negative
(n=19)
t/x² P value
Clinical features Arthritis 19 (86.4) 18 (94.7) 0.812 0.368
Pleurisy 14 (63.6) 13 (68.4) 0.104 0.747
Fever 14 (63.6) 7 (36.8) 2.930 0.087
Malar rash 11 (50.0) 14 (73.7) 2.403 0.121
Oral ulcers 12 (54.5) 9 (47.4) 0.21 0.647
Alopecia 10 (45.5) 9 (47.4) 0.015 0.902
Photosensitivity 6 (27.3) 11 (57.9) 3.939 0.047
Neurologic manifestations 5 (22.7) 6 (31.6) 0.407 0.524
APS 5 (22.7) 6 (31.6) 0.407 0.524
Vasculitis 8 (36.4) 1 (5.3) 5.756 0.016
Pericarditis 5 (22.7) 2 (10.5) 1.072 0.301
Discoid rash 3 (13.6) 1 (5.3) 0.812 0.368
Myositis 0 (0.0) 0 (0.0) -- --
Nephritis 15 (68.18) 8 (42.1) 3.051 0.217
ECLAM   4.6±2.1 3.1±2.1 2.254 0.030
Laboratory features ESR (mm/1st hour) 59.6±32.3 37.0±25.1 2.471 0.018
Serum creatinine (μmol/L ) 0.7±0.3 0.9±0.4 1.443 0.157
Serum albumin (g/dl) 3.6±0.5 4.2±0.8 2.960 0.005
Low C3 < 90 (mg/dl) 14 (63.6) 5 (26.3) 5.711 0.017
Low C4 < 10 (mg/dl) 7 (31.8) 5 (15.8) 1.420 0.233
24 hours urinary proteins (gm/24hrs) 2.1±2.0 1.6±1.5 0.606 0.551
  1. APS: Antiphospholipid syndrome, ESR: Erythrocyte sedimentation rate, ECLAM: European Consensus Lupus Activity Measurement